Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial.
Nadia Solowij, Samantha J Broyd, Camilla Beale, Julie-Anne Prick, Lisa-Marie Greenwood, Hendrika H Van Hell, Chao Suo, Peter Galettis, Nagesh Pai, Shanlin Fu, Rodney J. Croft, Jennifer H. Martin, Murat Yücel
Cannabis and Cannabinoid Research March 1, 2018 DOI: 10.1089/can.2017.0043 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Open-label pragmatic trial Peer reviewed |
|---|---|
| Sample size | 20 |
| Population | Community sample of regular cannabis users (16 male, median age 25 years; majority daily users with median 5.5 years of regular use) |
| Intervention | Cannabidiol (CBD) |
| Dose | 200 mg daily oral CBD |
| Duration | 10-week treatment, assessments at baseline and post-treatment |
| Topics | Cannabis CBD |
| Keywords | Memory Attention Psychological symptoms |
| Key findings | Prolonged daily CBD (200 mg) was well tolerated and was associated with significantly fewer depressive and psychotic-like symptoms and improved attentional switching, verbal learning, and memory in regular cannabis users, with no cognitive or psychological harms. Higher plasma CBD concentrations were associated with greater improvements in attentional control and psychological symptoms, and benefits were larger in dependent than nondependent users. The authors conclude CBD may be a useful adjunct for cannabis dependence but requires replication given the absence of a placebo control. |
Abstract
Introduction: Chronic cannabis use has been associated with impaired cognition and elevated psychological symptoms, particularly psychotic-like experiences. While Δ9-tetrahydrocannabinol (THC) is thought to be primarily responsible for these deleterious effects, cannabidiol (CBD) is purported to have antipsychotic properties and to ameliorate cognitive, symptomatic, and brain harms in cannabis users. However, this has never been tested in a prolonged administration trial in otherwise healthy cannabis users. Here, we report the first study of prolonged CBD administration to a community sample of regular cannabis users in a pragmatic trial investigating potential restorative effects of CBD on psychological symptoms and cognition.
Materials and Methods: Twenty frequent cannabis users (16 male, median age 25 years) underwent a 10-week open-label trial of 200 mg of daily oral CBD treatment, while continuing to use cannabis as usual. The majority of participants were daily cannabis users who had used cannabis for several years (median 5.5 years of regular use). Participants underwent psychological and cognitive assessments at baseline (BL) and post-treatment (PT) and were monitored weekly throughout the trial.
Results: CBD was well tolerated with no reported side effects; however, participants retrospectively reported reduced euphoria when smoking cannabis. No impairments to cognition were found, nor were there deleterious effects on psychological function. Importantly, participants reported significantly fewer depressive and psychotic-like symptoms at PT relative to BL, and exhibited improvements in attentional switching, verbal learning, and memory. Increased plasma CBD concentrations were associated with improvements in attentional control and beneficial changes in psychological symptoms. Greater benefits were observed in dependent than in nondependent cannabis users.
Conclusions: Prolonged CBD treatment appears to have promising therapeutic effects for improving psychological symptoms and cognition in regular cannabis users. Our findings require replication given the lack of a placebo control in this pragmatic trial, but suggest that CBD may be a useful adjunct treatment for cannabis dependence.
Comparable studies
Other non-randomized and open-label trials on CBD, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial. Individuals diagnosed with long COVID | 2024 | Single-arm open-label feasibility trial | n = 12 |
| Preventing new substance use behaviors in youth: evaluation of a two-year comprehensive program. Association workers and young people in France | 2024 | Pre-post intervention evaluation | n = 666 |
| Daily Cannabidiol Administration for 10 Weeks Modulates Hippocampal and Amygdalar Resting-State Functional Connectivity in Cannabis Users: A Functional Magnetic Resonance Imaging Open-Label Clinical Trial People who use cannabis | 2023 | Open-label pragmatic trial | n = 18 |
| Human Pharmacokinetics and Adverse Effects of Pulmonary and Intravenous THC-CBD Formulations Healthy volunteers | 2018 | Open-label, 2-period phase-1 pharmacokinetic study | n = 11 |
Citations in the library
Cited by 14
- Opposite Roles for Cannabidiol and δ-9-Tetrahydrocannabinol in Psychotomimetic Effects of Cannabis Extracts Journal of Clinical Psychopharmacology August 20, 2021
- The Effects of Cannabidiol and δ-9-Tetrahydrocannabinol in Social Cognition: A Naturalistic Controlled Study Cannabis and Cannabinoid Research July 26, 2022
- Personality, not cognition, distinguishes chronic ayahuasca and cannabis users from non-users European Neuropsychopharmacology February 12, 2026
- Avaliação das possíveis interações entre o canabidiol e a ayahuasca em voluntários saudáveis: um estudo randomizado, duplo-cego e controlado com placebo November 27, 2020
- Physical Activity Level Moderates Cannabis-Associated Reductions in Negative Affect in Anxious Individuals. Clinical Therapeutics September 2026
and 9 more in the library
Cites 12
- Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment Journal of Psychopharmacology October 5, 2012
- Acute Effects of a Single, Oral dose of d9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) Administration in Healthy Volunteers Current Pharmaceutical Design September 12, 2012
- Acute and Chronic Effects of Cannabinoids on Human Cognition-A Systematic Review. Biological Psychiatry April 1, 2016
- Hippocampal harms, protection and recovery following regular cannabis use. Translational Psychiatry January 12, 2016
- Cannabis with high cannabidiol content is associated with fewer psychotic experiences. Schizophrenia Research August 2011
and 7 more in the library